Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Aldeyra Therapeutics Inc (ALDX) Going to Burn These Hedge Funds?

Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed over the past few years. However, hedge funds are generally partially hedged and aim at delivering attractive risk-adjusted returns rather than following the ups and downs of equity markets, hoping that they will outperform the broader market. Our research shows that hedge funds do have great stock picking skills, so let’s take a glance at the smart money sentiment towards Aldeyra Therapeutics Inc (NASDAQ:ALDX).

Since the end of June, Aldeyra’s stock has advanced by more than 15%. However, the hedge fund interest in Aldeyra Therapeutics Inc (NASDAQ:ALDX) shares was flat at the end of last quarter. This is usually a negative indicator. The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity, but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as Amtech Systems, Inc. (NASDAQ:ASYS), Comstock Mining, Inc. (NYSEAMEX:LODE), and Cyren Ltd (NASDAQ:CYRN) to gather more data points.

Follow Aldeyra Therapeutics Inc. (NASDAQ:ALDX)
Trade (NASDAQ:ALDX) Now!

In the eyes of most shareholders, hedge funds are viewed as underperforming, old investment tools of years past. While there are more than an 8000 funds trading at the moment, Our researchers look at the crème de la crème of this club, approximately 700 funds. These investment experts watch over the lion’s share of the hedge fund industry’s total capital, and by monitoring their unrivaled investments, Insider Monkey has identified several investment strategies that have historically outperformed the broader indices. Insider Monkey’s small-cap hedge fund strategy surpassed the S&P 500 index by 12 percentage points annually for a decade in their back tests.

Now, let’s view the fresh action regarding Aldeyra Therapeutics Inc (NASDAQ:ALDX).

What have hedge funds been doing with Aldeyra Therapeutics Inc (NASDAQ:ALDX)?

At the end of the third quarter, a total of 7 of the hedge funds tracked by Insider Monkey were long this stock. Among these investors, Joseph Edelman’s Perceptive Advisors has the biggest position in Aldeyra Therapeutics Inc (NASDAQ:ALDX), worth close to $5.6 million, amounting to 0.4% of its total 13F portfolio. Coming in second is Deerfield Management, managed by James E. Flynn, which holds a $4 million position; 0.2% of its 13F portfolio is allocated to the stock. Other hedge funds and institutional investors that hold long positions encompass Julian Baker and Felix Baker’s Baker Bros. Advisors, Fred Knoll’s Knoll Capital Management, and Hal Mintz’s Sabby Capital.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.